These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35620187)

  • 41. Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review.
    Miao K; Zhang L
    Interdiscip Sci; 2021 Dec; 13(4):801-814. PubMed ID: 34152556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
    Front Immunol; 2021; 12():733530. PubMed ID: 34659220
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognosis after liver transplantation in patients treated with anti-PD-1 immunotherapy for advanced hepatocellular carcinoma: case series.
    Chen Z; Hong X; Wang T; Guo Y; Huang C; Li M; He X; Ju W; Chen M
    Ann Palliat Med; 2021 Sep; 10(9):9354-9361. PubMed ID: 34412496
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation - a multicenter cohort study.
    Shalaby S; Taborelli M; Zanetto A; Ferrarese A; D'Arcangelo F; Gambato M; Senzolo M; Russo FP; Germani G; Boccagni P; Ettorre GM; Baccarani U; Lauro A; Galatioto L; Rendina M; Petrara R; De Rossi A; Nudo F; Toti L; Fantola G; Vennarecci G; Risaliti A; Pinna AD; Gruttadauria S; Di Leo A; Rossi M; Tisone G; Zamboni F; Cillo U; Piselli P; Serraino D; Burra P;
    Transpl Int; 2021 Apr; 34(4):743-753. PubMed ID: 33492715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors.
    Personeni N; Pressiani T; D'Alessio A; Prete MG; Bozzarelli S; Terracciano L; Dal Buono A; Capogreco A; Aghemo A; Lleo A; Lutman RF; Roncalli M; Giordano L; Santoro A; Di Tommaso L; Rimassa L
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy.
    Lim N; Singh D; Jackson S; Lake JR
    Gastrointest Tumors; 2020 Oct; 7(4):134-143. PubMed ID: 33173777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Cui TM; Liu Y; Wang JB; Liu LX
    Onco Targets Ther; 2020; 13():11725-11740. PubMed ID: 33235462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation.
    Jin X; Ma X; Zhao D; Yang L; Ma N
    Transl Oncol; 2023 Feb; 28():101603. PubMed ID: 36542991
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
    Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
    Tejedor-Tejada J; Alonso-Martín C; Almohalla-Álvarez C; Valenzuela EF; Muñoz RN; Delgado LS; Martín CM; Sánchez-Martín F; García-Pajares F; Sánchez-Antolín G
    Transplant Proc; 2020 Jun; 52(5):1507-1510. PubMed ID: 32213292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant: An Italian Multicenter Experience.
    Invenizzi F; Iavarone M; Donato MF; Mazzucco A; Torre M; Conforti S; Rimessi A; Zavaglia C; Schiavon M; Comacchio G; Rea F; Boetto R; Cillo U; Dondossola D; De Carlis L; Lampertico P; Nosotti M; Mendogni P
    Front Oncol; 2020; 10():381. PubMed ID: 32351877
    [No Abstract]   [Full Text] [Related]  

  • 52. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Donor Polymorphisms of Toll-like Receptor 4 rs1927914 Associated with the Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.
    Shi G; Wang C; Zhang P; Ji L; Xu S; Tan X; Li H
    Arch Med Res; 2017 Aug; 48(6):553-560. PubMed ID: 29221801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
    Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
    Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection?
    Angelico R; Parente A; Manzia TM
    Transl Gastroenterol Hepatol; 2017; 2():74. PubMed ID: 29034347
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation.
    Lee SK; Jang JW; Nam H; Sung PS; Kim HY; Kwon JH; Lee SW; Song DS; Kim CW; Song MJ; Choi HJ; You YK; Bae SH; Choi JY; Yoon SK
    Hepatol Int; 2021 Feb; 15(1):137-145. PubMed ID: 33496932
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
    Yin X; Wu T; Lan Y; Yang W
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
    [TBL] [Abstract][Full Text] [Related]  

  • 58. When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road.
    Gu Y; Xu S; Wang Z; Yang J; Zheng S; Wei Q; Liu Z; Xu X
    Chin J Cancer Res; 2023 Apr; 35(2):92-107. PubMed ID: 37180832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pre-Transplant Factors Influencing Rates of Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients.
    Zucker KM; Gomez PA; Kezirian O; Mehta S
    Gastroenterology Res; 2021 Jun; 14(3):190-193. PubMed ID: 34267835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation.
    Zou WL; Zang YJ; Chen XG; Shen ZY
    Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):145-51. PubMed ID: 18397848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.